NCT06483282View on ClinicalTrials.gov

A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

June 21, 2024

Primary Completion Date

June 1, 2026

Study Completion Date

December 31, 2026

Conditions
Small Cell Lung Cancer Limited Stage
Interventions
DRUG

Adebrelimab

This product is administered by intravenously guttae. The recommended dose of subcutaneous injection is 20mg/kg, administered every 3 Weeks (Q3W).

DRUG

Apatinib Mesylate

This product is an orally administered targeted therapy drug, with a recommended dosage of one tablet per day.

DRUG

Etoposide

This product is administered by intravenously guttae. The recommended dose of subcutaneous injection is 100mg/m2, administered every 3 Weeks (Q3W).

DRUG

Carboplatin

This product is administered by intravenously guttae. AUC=5, administered every 3 Weeks (Q3W).

Trial Locations (1)

Unknown

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors
lead

Jin Ying

OTHER